NCT04917549

Prevalence of Oral Lesions in COVID-19 Patients

Completed Last updated 4 April 2022

What this trial tests

trial testing detection of oral lesions in Oral Lesions in 124 participants. Completed in 10 June 2021.

Timeline

2 September 2020

Primary endpoint
10 June 2021

10 June 2021

Quick facts

Lead sponsor	Kafrelsheikh University
Status	Completed
Study type	OBSERVATIONAL
Enrollment	124
Start date	2 September 2020
Primary completion	10 June 2021
Estimated completion	10 June 2021
Sites	1 location across Egypt

Drugs / interventions tested

• detection of oral lesions

Conditions studied

• Oral Lesions — all drugs for Oral Lesions →
• COVID-19 — all drugs for COVID-19 →
• Angiotensin-converting Enzyme 2 — all drugs for Angiotensin-converting Enzyme 2 →

Sponsor

Kafrelsheikh University

Who can join

18 and older, any sex, with Oral Lesions or COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Recently, a new coronavirus disease 2019 (COVID-19) has appeared and caused an unprecedented pandemic which is considered as an urgent threat to health authorities worldwide. Several symptoms are observed which are fever, cough, shortness of breath, headache, runny nose, muscle pain, fatigue, arthralgia, sputum production, conjunctivitis, diarrhea. Susceptibility, genetics, systematic diseases, population, gender, and age are crucial considerations for the onset and progression of the viral infection. The patients suffering from asthma or pulmonary deficiency are at high risk of mortality. A metallopeptidase, angiotensin-converting enzyme 2 (ACE2) is considered as the functional receptor for SARS-CoV-2 and it was isolated from a COVID-19 patient. ACE2 was recognized in type I and type II alveolar epithelial cells in both nasal and oral mucosa, in the nasopharynx, in the smooth muscle cells and endothelium of vessels in the stomach and the skin, distinctly in the basal cell layer of the epidermis extending to the basal cell layer of hair follicles, and in the basal layer of the non-keratinizing squamous epithelium. In order to study the possible routes of SARS-CoV-2 infection on the oral mucosa, we investigated whether oral lesions mainly affect the tongue mucosa due to higher ACE2-expressing cell composition and proportion more than that in other oral tissues. Moreover, appearance of oral lesions were as a result of SARS-CoV-2 infection or as a side effect of certain drugs for COVID-19 treatment was evaluated.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Prevalence of Oral Lesions in COVID-19 Egyptian Patients.
   Elamrousy WAH, Nassar M, Issa DR. · · 2021 · cited 5× · PMID 35036381 · DOI 10.4103/jispcd.jispcd_221_21